Related Experiment Video
Updated: Aug 1, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Systemic tobramycin concentrations during selective decontamination of the digestive tract in intensive care unit
Meriel Mol1, Hendrikus J M van Kan, Marcus J Schultz
1Department of Intensive Care, Academic Medical Centre University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. m.mol@amc.uva.nl
Objective:
To study whether selective decontamination of the digestive tract (SDD) results in detectable serum tobramycin concentrations in intensive care unit (ICU) patients with acute renal failure treated with continuous venovenous hemofiltration (CVVH).
Design And Setting:
Prospective, observational, single-center study in a mixed medical-surgical ICU.
Patients:
Adult ICU patients receiving SDD for at least 3 days and being treated with CVVH because of acute renal failure.
Measurements And Results:
Tobramycin serum concentrations were measured at the 3rd day after start of CVVH and every 3 days thereafter. Detectable serum concentrations of tobramycin were found in 12 (63%) of 19 patients and in 15 (58%) of the 26 samples. With a toxic tobramycin concentration defined as more than 2.0 mg/l, we found one patient with a toxic concentration of 3.0 mg/l. In three other patients tobramycin concentrations of >or=1.0 mg/l were found.
Conclusions:
In patients with acute renal failure treated with CVVH, administration of SDD with tobramycin can lead to detectable and potentially toxic serum tobramycin concentrations.
Related Concept Videos
Drug Elimination by Renal Route: Tubular Secretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
Hemodialysis III: Nursing Management

